Drug Information

Drug General Information
Drug ID
D0P4KU
Former ID
DNCL002447
Drug Name
ABI-011
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Phase 1 [523113]
Company
Celgene
Target and Pathway
Target(s) Toposisomerase-1 Target Info Modulator
Tubulin beta Target Info Modulator
KEGG Pathway Phagosome
Gap junction
Pathogenic Escherichia coli infection
NetPath Pathway IL2 Signaling PathwayNetPath_25:FSH Signaling Pathway
TCR Signaling Pathway
EGFR1 Signaling Pathway
PANTHER Pathway DNA replicationP00016:Cytoskeletal regulation by Rho GTPase
Huntington disease
Pathway Interaction Database Caspase Cascade in Apoptosis
Reactome Regulation of PLK1 Activity at G2/M Transition
Loss of Nlp from mitotic centrosomes
Recruitment of mitotic centrosome proteins and complexes
Loss of proteins required for interphase microtubule organization?from the centrosome
Anchoring of the basal body to the plasma membrane
WikiPathways Integrated Pancreatic Cancer PathwayWP2359:Parkin-Ubiquitin Proteasomal System pathway
Pathogenic Escherichia coli infection
Mitotic G2-G2/M phases
References
Ref 523113ClinicalTrials.gov (NCT01163071) A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas. U.S. National Institutes of Health.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.